KIMS - Krishna Institute of Medical Sciences Limited Share Price

Healthcare Services

₹671.25-3.30(-0.49%)

Market Closed as of Apr 28, 2025, 15:30 IST

What does Krishna Institute of Medical Sciences Limited do?

Hospital•Healthcare•Small Cap

Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reproductive, and robotic sciences, as well as gastroenterology and hepatology, heart and lung transplant, organ transplantation, mother and childcare, and pediatrics services. It focuses on accident, biochemistry, anesthesiology, bariatric surgery, andrology and infertility, arthroscopy, Alzheimer's, bone, joint center specialties, and others. In addition, the company provides medical procedures for aneurysm, ankle arthritis and total ankle replacement, anterior cervical discectomy and fusion surgery, anterior resection, aortic aneurysm, aortic stent graft, aortic valve replacement, arthroscopy, atrial septal defect, bariatric surgery, and others. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.

Industry Group:Healthcare Services

Employees:5,013

Website:www.kimshospitals.com

Balance Sheet for Krishna Institute of Medical Sciences

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	-10.5%	18	20	22	38	55	20
Current investments	-101.6%	0	62	43	41	20	0
Loans, current	-54.6%	4.7	9.15	0	0	15	6.64
Total current financial assets	-15.1%	237	279	212	213	276	297
Inventories	-4.8%	21	22	25	19	20	26
Current tax assets	-137.7%	0	3.65	0	0	0	0
Total current assets	-9.5%	276	305	257	237	304	331
Property, plant and equipment	1%	633	627	601	593	578	580
Capital work-in-progress	20.3%	351	292	17	16	23	13
Investment property	-	0	0	0	0	0	0
Non-current investments	13.5%	1,136	1,001	836	785	673	542
Loans, non-current	115.8%	206	96	107	88	80	66
Total non-current financial assets	23.1%	1,361	1,106	956	882	765	627
Total non-current assets	18.1%	2,470	2,092	1,709	1,575	1,401	1,238
Total assets	14.7%	2,747	2,396	1,966	1,812	1,705	1,569
Borrowings, non-current	44.9%	372	257	0	0	0	4.17
Total non-current financial liabilities	45.5%	388	267	0.02	0.01	0.01	4.18
Provisions, non-current	16.7%	22	19	18	17	16	15
Total non-current liabilities	37.2%	440	321	62	62	58	57
Borrowings, current	70.6%	117	69	0	4.17	11	14
Total current financial liabilities	53%	252	165	107	89	125	104
Provisions, current	11.1%	11	10	6.87	7.8	6.73	6.79
Current tax liabilities	-	11	0	3.48	0	0.94	0
Total current liabilities	47.6%	308	209	144	120	155	134
Total liabilities	41.4%	749	530	206	181	213	191
Equity share capital	0%	80	80	80	80	80	80
Total equity	7.1%	1,998	1,866	1,760	1,631	1,491	1,378
Total equity and liabilities	14.7%	2,747	2,396	1,966	1,812	1,705	1,569

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	34.8%	63	47	38	62	101	26
Current investments	-85.4%	13	83	66	68	60	0
Loans, current	-	0	0	0	0	0	0
Total current financial assets	14.5%	529	462	440	423	493	347
Inventories	10.4%	54	49	50	43	45	36
Current tax assets	-102.2%	0	46	35	0	0	0
Total current assets	5.4%	625	593	560	478	554	393
Property, plant and equipment	6.8%	1,847	1,730	1,233	1,381	1,392	771
Capital work-in-progress	42.4%	854	600	638	477	126	21
Investment property	-	0	0	0	0	0	0
Goodwill	23.1%	379	308	308	308	308	85
Non-current investments	-100.5%	0.6	74	50	0	0	332
Loans, non-current	156%	65	26	0	0	0	0
Total non-current financial assets	-24%	147	193	88	57	43	372
Total non-current assets	21.3%	3,954	3,259	2,859	2,464	2,140	1,514
Total assets	18.9%	4,579	3,852	3,419	2,941	2,694	1,907
Borrowings, non-current	27.3%	1,560	1,226	901	634	436	138
Total non-current financial liabilities	27.4%	1,570	1,233	901	634	438	227
Provisions, non-current	23.1%	33	27	25	24	22	17
Total non-current liabilities	25.4%	1,638	1,306	974	707	508	282
Borrowings, current	72.7%	222	129	54	45	40	23
Total current financial liabilities	49.5%	578	387	301	249	287	177
Provisions, current	5.6%	20	19	14	14	12	10
Current tax liabilities	-	12	0	6.9	0	0.94	0.17
Total current liabilities	45.7%	658	452	360	296	333	215
Total liabilities	30.5%	2,296	1,759	1,334	1,003	841	497
Equity share capital	0%	80	80	80	80	80	80
Non controlling interest	6.1%	281	265	271	268	287	23
Total equity	9.1%	2,283	2,093	2,085	1,938	1,853	1,411
Total equity and liabilities	18.9%	4,579	3,852	3,419	2,941	2,694	1,907

Income Statement for Krishna Institute of Medical Sciences

Standalone figures (in Rs. Crores) / View Consolidated Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	8%	1,222	1,132	1,143	933
Other Income	-34.8%	16	24	24	9.62
Total Income	7.1%	1,238	1,156	1,168	942
Cost of Materials	-	0	0	0	196
Purchases of stock-in-trade	10%	254	231	259	0
Employee Expense	17.7%	220	187	174	147
Finance costs	1673.3%	3.66	1.15	4.47	15
Depreciation and Amortization	29.5%	58	45	45	45
Other expenses	11.6%	387	347	323	280
Total Expenses	12.4%	919	818	797	688
Profit Before exceptional items and Tax	-5.7%	318	337	371	254
Total profit before tax	-5.7%	318	337	371	254
Current tax	-1.2%	83	84	91	67
Deferred tax	-2150%	-0.64	1.08	1.71	-1.2
Total tax	-2.4%	83	85	93	66
Total profit (loss) for period	-6.8%	235	252	278	189
Other comp. income net of taxes	-316.7%	0.25	0.82	0.2	-0.48
Total Comprehensive Income	-6.7%	236	253	279	188
Earnings Per Share, Basic	-8.1%	5.882	6.31	78	5.04
Earnings Per Share, Diluted	-8.1%	5.882	6.31	78	4.954

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	-4.1%	348	363	327	305	302	316
Other Income	257.1%	21	6.6	5.3	3.9	4.23	3.57
Total Income	-0.5%	368	370	333	309	306	320
Purchases of stock-in-trade	8.8%	75	69	64	59	61	67
Employee Expense	-5.1%	57	60	62	56	54	56
Finance costs	58.3%	6.7	4.6	3.8	2.31	1.22	0.05
Depreciation and Amortization	7.7%	15	14	14	20	13	13
Other expenses	-3.3%	118	122	109	102	98	96
Total Expenses	-1.9%	266	271	251	241	229	231
Profit Before exceptional items and Tax	3.1%	102	99	82	67	78	89
Total profit before tax	3.1%	102	99	82	67	78	89
Current tax	-17.9%	24	29	22	20	19	23
Deferred tax	123.5%	1.8	-2.4	-0.9	-0.48	0.1	-0.48
Total tax	-7.7%	25	27	21	19	19	23
Total profit (loss) for period	5.6%	76	72	61	48	58	66
Other comp. income net of taxes	32%	-0.7	-1.5	0.1	-0.33	0.2	0.18
Total Comprehensive Income	7.1%	76	71	61	48	59	66
Earnings Per Share, Basic	13.7%	1.91	1.8	1.516	1.204	1.458	1.654
Earnings Per Share, Diluted	13.7%	1.91	1.8	1.516	1.204	1.458	1.654

Consolidated figures (in Rs. Crores) / View Standalone Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	13.7%	2,498	2,198	1,651	1,330
Other Income	-52%	13	26	20	10
Total Income	12.9%	2,511	2,224	1,671	1,340
Cost of Materials	-	0	0	0	283
Purchases of stock-in-trade	13.3%	537	474	368	0
Employee Expense	22%	422	346	262	220
Finance costs	53.3%	47	31	16	32
Depreciation and Amortization	14.1%	147	129	73	70
Other expenses	18%	905	767	518	450
Total Expenses	17%	2,051	1,753	1,224	1,061
Profit Before exceptional items and Tax	-2.1%	460	470	447	279
Exceptional items before tax	-107.1%	0	15	0	0
Total profit before tax	-5.2%	460	485	447	279
Current tax	2.6%	120	117	114	78
Deferred tax	104.7%	4.03	2.48	0.17	-4.3
Total tax	4.2%	124	119	114	74
Total profit (loss) for period	-8.2%	336	366	344	205
Other comp. income net of taxes	-346.7%	0.33	0.85	0.12	-0.46
Total Comprehensive Income	-8.5%	336	367	344	205
Earnings Per Share, Basic	-8.9%	7.75	8.406	8.376	5.374
Earnings Per Share, Diluted	-8.9%	7.75	8.406	8.376	5.24

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	-0.6%	772	777	688	634	606	652
Other Income	325%	18	5	4.6	3.81	3.26	2.88
Total Income	1%	790	782	693	638	609	655
Purchases of stock-in-trade	8.3%	170	157	145	135	124	143
Employee Expense	7.6%	128	119	119	109	104	106
Finance costs	31.6%	26	20	18	16	12	8.91
Depreciation and Amortization	10%	45	41	39	46	35	33
Other expenses	4.2%	296	284	248	232	229	229
Total Expenses	5.8%	656	620	566	537	507	517
Profit Before exceptional items and Tax	-16.8%	135	162	127	100	103	139
Exceptional items before tax	-	0	0	0	0	0	-0.02
Total profit before tax	-16.8%	135	162	127	100	103	139
Current tax	-22.7%	35	45	34	29	22	37
Deferred tax	228.9%	6.8	-3.5	-1.9	-0.2	4.05	0.17
Total tax	0%	42	42	32	28	26	37
Total profit (loss) for period	-24.2%	92	121	95	71	77	101
Other comp. income net of taxes	42.4%	-0.9	-2.3	0.1	-0.27	0.23	0.19
Total Comprehensive Income	-22.2%	92	118	95	71	77	101
Earnings Per Share, Basic	-27.4%	2.22	2.68	2.164	1.636	1.796	2.3
Earnings Per Share, Diluted	-27.4%	2.22	2.68	2.164	1.636	1.796	2.3

Valuation
Market Cap	26.86 kCr
Price/Earnings (Trailing)	70.7
Price/Sales (Trailing)	9.25
EV/EBITDA	34.66
Price/Free Cashflow	-175.65
MarketCap/EBT	51.26

Fundamentals
Revenue (TTM)	2.9 kCr
Rev. Growth (Yr)	29.73%
Rev. Growth (Qtr)	1.01%
Earnings (TTM)	379.89 Cr
Earnings Growth (Yr)	20.83%
Earnings Growth (Qtr)	-23.36%

Profitability
Operating Margin	18.05%
EBT Margin	18.05%
Return on Equity	16.64%
Return on Assets	8.3%
Free Cashflow Yield	-0.57%

Pros

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Balance Sheet: Strong Balance Sheet.

Size: Market Cap wise it is among the top 20% companies of india.

Momentum: Stock price has a strong positive momentum. Stock is up 10.1% in last 30 days.

Smart Money: Smart money has been increasing their position in the stock.

Profitability: Recent profitability of 13% is a good sign.

Growth: Awesome revenue growth! Revenue grew 18.3% over last year and 124.9% in last three years on TTM basis.

Cons

Dividend: Stock hasn't been paying any dividend.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Sector Comparison: KIMS vs Healthcare Services

Comprehensive comparison against sector averages

Comparative Metrics

KIMS metrics compared to Healthcare

Category	KIMS	Healthcare
PE	71.05	37.86
PS	9.30	6.83
Growth	18.3 %	-1.3 %

Performance Comparison

KIMS vs Healthcare (2022 - 2025)

Key Insights

1. KIMS is among the Top 10 Hospital companies but not in Top 5.
2. The company holds a market share of 4.6% in Hospital.
3. In last one year, the company has had an above average growth that other Hospital companies.

Investor Care
Shares Dilution (1Y)	0.00%
Diluted EPS (TTM)	8.7

Financial Health
Current Ratio	0.95
Debt/Equity	0.78

Summary of Latest Earnings Report from Krishna Institute of Medical Sciences

Summary of Krishna Institute of Medical Sciences's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated: Feb 25

Outlook and Major Points from KIMS Management:

1. Expansion and Growth Plans:

New Facilities: Opened a 200-bed hospital in Guntur (O&M model) and acquired VIMS (300 beds) in Kerala. Kannur hospital (Kerala) reached breakeven in 3 months.
Upcoming Projects: Thane (300 beds) and two Bangalore hospitals (total 650 beds) expected to start operations in Q1/Q2 FY26 to minimize pre-opening losses. Kerala expansions (Kollam, Thrissur) and Karnataka (Sarjapur, North Bangalore) targeted for tertiary/quaternary care.
Geographic Focus: Aiming for 2,000"“3,000 beds in Kerala/Karnataka over time, with plans for Kochi and Calicut.

2. Financial Guidance:

Margins: AP cluster margins expected to improve to ~30% in 2"“3 years with oncology additions. Telangana margins to benefit from Sunshine ramp-up (targeting 30"“33%).
Loss Mitigation: Nashik (Maharashtra) to breakeven by Q2/Q3 FY26; new projects (Thane, Bangalore) may incur ~INR 10"“15 crore loss each in FY26.
Debt/CAPEX: Debt at INR 1,550 crore (Dec 2024), targeting <2x debt/EBITDA. FY26 CAPEX remains on track with INR 500"“600 crore guidance.

3. Operational Efficiency:

ARPOB Growth: Focus on reducing ALOS (3.5 to 3.3 days) to boost ARPOB.
Tech Advancements: South Asia's first MRI-guided ultrasound for Parkinson's, 100+ robotic surgeries, and AI-driven innovations.

4. Market Dynamics:

Competition: Confident in Thane's demand despite new entrants; sees 4"“5-year runway for growth.
Medical Tourism: Targeting INR 100"“150 crore revenue from international patients via Bangalore/Thane expansions.

5. One-Time Impacts:

Write-offs (INR 8"“9 crore in Q3) largely addressed; minimal future provisions.
Maharashtra EBITDA dip due to Nashik losses (INR 5 crore in Q3) and seasonal declines in Nagpur.

6. Leadership & Governance:

New board member (Suresh Patel, ex-CVC) to strengthen governance.

Management remains focused on disciplined expansion, margin improvement, and leveraging technology for sustainable growth.

Q&A Session

Last updated: Feb 25

Question: My first question is on the Maharashtra cluster. Is there any one-off there? I see a sharp decline in the EBITDA margins here. And what could be the EBITDA loss in the Nashik unit?
Answer: The Maharashtra cluster's EBITDA decline was due to seasonal impacts in Nagpur and a one-off provision/write-off of ~INR 3.5 crore. Nashik's quarterly loss was INR 5 crore, with breakeven expected by Q2/Q3 FY26.

Question: Could you please provide some colour on corporate overheads? Has there been a surge due to new hiring, and how will this trend?
Answer: Corporate overheads did not rise materially except for one-time expenses (INR 8"“9 crore) for provisions/write-offs. Preoperative costs for new clusters (e.g., Bangalore) are not yet impacting P&L.

Question: How should we think about ARPOB growth in Telangana and AP clusters for FY26/27?
Answer: ARPOB growth will continue through reduced ALOS (targeting 3.3"“3.4 days vs. 3.5) and case-mix improvements. Growth rates align with historical trends.

Question: What is the performance update on Sunshine Hospitals (Telangana cluster)?
Answer: Sunshine reported Q3 revenue of INR 150 crore (vs. INR 158 crore in Q2) and EBITDA of INR 40 crore (vs. INR 48 crore). Occupancy remains stable, with Begumpet performing well.

Question: How is KIMS perceived"”as multi-specialty or focused on specific therapies?
Answer: KIMS is viewed as multi-specialty, with cardiac (17"“18%) and other specialties (9"“10% each) contributing diversely. No single specialty dominates revenue.

Question: What are the timelines and ARPOB expectations for Kerala units (Kollam, Thrissur)?
Answer: Kollam will rebrand by April 2025, targeting tertiary care. Thrissur starts in 12"“15 months. Mature ARPOB for Kerala hospitals is projected at ~INR 30,000"“33,000, similar to Nagpur.

Question: How has Queen's NRI (AP cluster) performed post-acquisition?
Answer: Queen's NRI is EBITDA-neutral with 35"“40% occupancy. Renovations and doctor onboarding (completed by Feb/March 2025) will drive FY26 ramp-up.

Question: What is the loss guidance for new hospitals (Thane, Bangalore) in FY26?
Answer: Each new hospital (Thane, Bangalore 1 & 2) may incur INR 10"“15 crore EBITDA loss in FY26, totaling ~INR 30"“45 crore. Losses taper by FY27.

Question: How will debt and interest costs trend amid expansions?
Answer: Debt stands at INR 1,550 crore (Dec 2024), peaking at ~INR 1,750 crore. Debt/EBITDA remains under 2x, with normalization post-2026 as new units mature.

Question: What is KIMS' medical tourism strategy and revenue contribution?
Answer: International patient revenue is INR 40"“50 crore annually (Telangana). Bangalore and Thane expansions aim to boost this to INR 100"“150 crore, though EBITDA contribution remains minimal currently.

Question: Why is oncology delayed in new Kerala/Maharashtra hospitals?
Answer: Nashik excludes oncology due to contractual terms. Kerala's existing facilities lack space, but greenfield projects (e.g., Bangalore, Thane) include oncology from Day 1.

Question: Can AP cluster margins match Telangana's (30%+)?
Answer: AP margins (24% YTD) may reach 30% in 2"“3 years as oncology/mother-child care ramp up. Structural gaps (e.g., Tier-2 markets) may sustain a ~300"“400 bps difference.

Share Holdings

Understand Krishna Institute of Medical Sciences ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

As of 2025-03-31

Shareholder Name	Holding %
Bhaskara Rao Bollineni	26.27%
SBI Small Cap Fund	6.31%
Bluebridge Capital Private Limited	6.05%
Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund	5.17%
Hdfc Small Cap Fund	4.49%
Bollineni Seenaiah Naidu	4.27%
Sbi Life Insurance Co. Ltd	3.52%
Kotak Small Cap Fund	3.07%
Lilac Investments Limited	1.96%
Amansa Holdings Private Limited	1.93%
Nomura India Investment Fund Mother Fund	1.72%
Rajyasri Bollineni	1.72%
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund	1.67%
Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 110	1.4%
Venkata Krishna Kumar Kodali	1.26%
Hdfc Life Insurance Company Limited	1.19%
B Krishnaiah	0.22%
Bollineni Aishwarya	0.18%
Abhinay Bollineni	0.06%
Sujatha Bollineni	0.04%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Cash Flow for Krishna Institute of Medical Sciences

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	1673.3%	3.66	1.15	4.47
Change in inventories	-167.4%	-2.87	6.74	-11.59
Depreciation	29.5%	58	45	45
Impairment loss / reversal	-	-2.68	0	0
Dividend income	-35.1%	0	0.26	0
Adjustments for interest income	-15.5%	9.45	11	17
Net Cashflows from Operations	-30.9%	348	503	436
Dividends received	-35.1%	0	0.26	0
Income taxes paid (refund)	13.5%	85	75	0
Net Cashflows From Operating Activities	-39%	262	429	436
Cashflows used in obtaining control of subsidiaries	-8.6%	214	234	0
Proceeds from sales of PPE	16.1%	0.53	0.44	0.24
Purchase of property, plant and equipment	166.7%	321	121	69
Cash receipts from repayment of advances and loans made to other parties	-138.5%	-37.5	101	142
Interest received	-93.3%	1.8	13	16
Income taxes paid (refund)	-	0	0	96
Other inflows (outflows) of cash	102.1%	1.85	-39.52	0
Net Cashflows From Investing Activities	-43.8%	-568.65	-395.03	-527.21
Proceeds from issuing shares	-	0	0	192
Proceeds from borrowings	-	326	0	0
Repayments of borrowings	-75.6%	4.17	14	110
Payments of lease liabilities	-	29	0	0
Interest paid	2087.5%	4.5	1.16	4.22
Net Cashflows from Financing Activities	1857.2%	289	-15.39	76
Net change in cash and cash eq.	-209.5%	-17.62	18	-14.73

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	53.3%	47	31	16
Change in inventories	-238.6%	-6.58	6.47	-12.34
Depreciation	14.1%	147	129	73
Impairment loss / reversal	-	-1.46	0	0
Adjustments for interest income	-84.9%	2.29	9.53	12
Net Cashflows from Operations	24.8%	661	530	520
Interest received	71%	0	-2.45	0
Income taxes paid (refund)	47.9%	140	95	0
Net Cashflows From Operating Activities	20.6%	521	432	520
Cashflows used in obtaining control of subsidiaries	-65.6%	75	216	0
Proceeds from sales of PPE	-74.8%	1.41	2.63	0.32
Purchase of property, plant and equipment	23%	647	526	170
Purchase of intangible assets	-102.1%	0	49	0
Interest received	-94%	1.6	11	13
Income taxes paid (refund)	-	0	0	127
Other inflows (outflows) of cash	-105.3%	-7.53	162	0
Net Cashflows From Investing Activities	-22.2%	-752.56	-615.6	-606.48
Payments from changes in ownership interests in subsidiaries	-	181	0	1.13
Proceeds from issuing shares	-	0	0	192
Proceeds from borrowings	36.6%	531	389	124
Repayments of borrowings	-92.9%	18	241	233
Payments of lease liabilities	37.5%	56	41	0
Interest paid	222.2%	59	19	12
Net Cashflows from Financing Activities	148.3%	217	88	60
Net change in cash and cash eq.	83.7%	-14.72	-95.17	-26.5

Is Krishna Institute of Medical Sciences Better than it's peers?

Detailed comparison of Krishna Institute of Medical Sciences against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
APOLLOHOSP	Apollo Hospitals EnterprisesHospital	1.01 LCr	21.31 kCr	+6.39%	+8.65%	75.09	4.75	+15.13%	+64.06%
FORTIS	Fortis HealthcareHospital	50.97 kCr	7.62 kCr	+1.39%	+47.16%	61.83	6.69	+12.17%	+42.06%
NH	Narayana HrudayalayaHospital	36.75 kCr	5.48 kCr	+9.70%	+41.17%	46.87	6.71	+8.88%	+1.56%
MEDANTA	Global HealthHospital	32.26 kCr	3.65 kCr	-0.46%	-15.57%	63.6	8.83	+12.56%	+12.29%
HCG	HealthCare Global EnterprisesHospital	7.75 kCr	2.16 kCr	+8.06%	+56.37%	118.29	3.58	+15.26%	+178.69%

KIMS - Krishna Institute of Medical Sciences Limited Share Price

What does Krishna Institute of Medical Sciences Limited do?

Balance Sheet for Krishna Institute of Medical Sciences

Income Statement for Krishna Institute of Medical Sciences

Valuation

Fundamentals

Profitability

Sector Comparison: KIMS vs Healthcare Services

Comparative Metrics

Performance Comparison

Investor Care

Financial Health

Summary of Latest Earnings Report from Krishna Institute of Medical Sciences

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Cash Flow for Krishna Institute of Medical Sciences

Is Krishna Institute of Medical Sciences Better than it's peers?

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)